{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:37:58Z","timestamp":1792715878978,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.esmoop.2026.108530","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:54:41Z","timestamp":1789588481000},"page":"108530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Zolbetuximab plus chemotherapy versus immune checkpoint inhibitor regimens by programmed death-ligand 1 combined positive score in locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: a Bayesian network meta-analysis"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3630","authenticated-orcid":false,"given":"K.","family":"Shitara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-4531","authenticated-orcid":false,"given":"S.Y.","family":"Rha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4062-0808","authenticated-orcid":false,"given":"S.J.","family":"Klempner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-9339","authenticated-orcid":false,"given":"F.","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ranganath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.H.","family":"Getzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gourgioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2026.108530_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2026.108530_bib2","series-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","year":"2024"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108530_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108530_bib4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108530_bib5","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10294","key":"10.1016\/j.esmoop.2026.108530_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2026.108530_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108530_bib8","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/curroncol32110648","article-title":"Zolbetuximab or immunotherapy as the initial targeted therapy in CLDN18.2-positive, HER2-negative advanced gastric cancer: weighing the options","volume":"32","author":"Easaw","year":"2025","journal-title":"Curr Oncol"},{"issue":"10389","key":"10.1016\/j.esmoop.2026.108530_bib10","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108530_bib11","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108530_bib12","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1056\/NEJMc2409512","article-title":"Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma","volume":"391","author":"Shitara","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108530_bib13","series-title":"VYLOY\u00ae (zolbetuximab-clzb) [package insert]","year":"2024"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108530_bib14","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/aje\/kwae260","article-title":"Introduction to network meta-analysis: understanding what it is, how it is done, and how it can be used for decision-making","volume":"194","author":"Brignardello-Petersen","year":"2024","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108530_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value in Health"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2026.108530_bib16","article-title":"Network meta-analysis of global trials of 1L therapies in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma","volume":"42","author":"Shah","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108530_bib17","series-title":"NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"Dias","year":"2014"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108530_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jval.2014.01.004","article-title":"Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report","volume":"17","author":"Jansen","year":"2014","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108530_bib19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(10)70065-7","article-title":"Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care","volume":"10","author":"Tacconelli","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.esmoop.2026.108530_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105931","article-title":"Impact and effective management of nausea\/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies","author":"Shitara","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108530_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.05.007","article-title":"A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer","volume":"100","author":"Sahin","year":"2018","journal-title":"Eur J Cancer"},{"issue":"23","key":"10.1016\/j.esmoop.2026.108530_bib23","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108530_bib25","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1016\/j.annonc.2025.05.433","article-title":"417P Comparative efficacy and safety of tislelizumab (TIS) vs other anti\u2013PD-1 treatments in first-line (1L) gastric or gastroesophageal junction cancer (GC\/GEJC): a network meta-analysis (NMA)","volume":"36","author":"Maqueda","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108530_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108530_bib29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108530_bib30","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/aje\/kwab278","article-title":"Introducing the treatment hierarchy question in network meta-analysis","volume":"191","author":"Salanti","year":"2022","journal-title":"Am J Epidemiol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108530_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103967","article-title":"PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma: a systematic review and meta-analysis of seven phase III randomized trials","volume":"9","author":"Formica","year":"2024","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108530_bib32","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1001\/jamaoncol.2020.1046","article-title":"Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: a systematic review and meta-analysis","volume":"6","author":"Petrelli","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108530_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.106053","article-title":"Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with clinical outcomes in a European cohort","volume":"11","author":"Ter\u00e1n","year":"2026","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108530_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100844","article-title":"Analytical and clinical performance of the VENTANA CLDN18 (43-14A) RxDx assay in gastric and gastroesophageal junction adenocarcinoma tissue samples in SPOTLIGHT and GLOW","volume":"38","author":"Stratton","year":"2025","journal-title":"Mod Pathol"},{"key":"10.1016\/j.esmoop.2026.108530_bib35","article-title":"The prognostic role of Claudin 18.2 in advanced gastric or gastroesophageal junction adenocarcinoma: a systematic literature review","volume":"9","author":"Fassan","year":"2025","journal-title":"ESMO Gastrointest Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108530_bib36","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","article-title":"Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Shitara","year":"2024","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.esmoop.2026.108530_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.2763","article-title":"2144P Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with immunotherapy outcomes: a multicenter study","volume":"36","author":"Ter\u00e1n Brage","year":"2025","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.esmoop.2026.108530_bib39","article-title":"Zolbetuximab + pembrolizumab and chemotherapy as first-line treatment for patients with CLDN18.2-positive, HER2-negative, PD-L1-positive locally advanced unresectable or metastatic G\/GEJ adenocarcinoma: phase 3, double-blind, randomized trial (LUCERNA)","volume":"44","author":"Shitara","year":"2026","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108530_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006500","article-title":"Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review","volume":"11","author":"Barron","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108530_bib41","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Spain L.,et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108530_bib42","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2023.7103","article-title":"Gastroesophageal adenocarcinomas with defective mismatch repair: current knowledge and clinical management","volume":"22","author":"Strickland","year":"2024","journal-title":"J Natl Compr Canc Netw"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926024750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926024750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:42:29Z","timestamp":1792712549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926024750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2059702926024750"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108530","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zolbetuximab plus chemotherapy versus immune checkpoint inhibitor regimens by programmed death-ligand 1 combined positive score in locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: a Bayesian network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108530"}}